This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
By This Author:
« Back
Page 1 of 2

The Run-Up Trade: Biodel's Insulin Trial Results

By Mark Messier

Biodel shares should move higher ahead of insulin trial results in the third quarter.

08:00AM 05/30/13

Rockwell Medical Run-Up Trade Follows Financing

By Mark Messier

One trader believes Rockwell shares will rise into clinical trial results expected in July.

08:00AM 05/21/13

Synta Is Run-Up to ASCO Lung Cancer Data

By Mark Messier

The market overreacted to the resignation of Synta's R&D chief.

10:16AM 05/14/13

Expecting Ziopharm Shares To Run Into Phase III Data At Month's End

By Mark Messier

Ziopharm is an example of a stock with clinical trial results that can be traded realtively safely.

07:00AM 03/04/13

Run-Up Trade Into Dynavax's FDA Approval Decision

By Mark Messier

Three factors that will cause Dynavax shares to gain as get closer to the approval of its Hep B vaccine.

07:00AM 02/13/13

Titan Pharma: Run-Up Trade Into March FDA Panel

By Mark Messier

I expect traders will get an opportunity to profit from increased focus on Titan through March.

06:03AM 01/31/13

A.P. Pharma Run-Up Trade Into FDA Approval Decision

By Mark Messier

Look at A.P. Pharma as a trade, not as a long-term investment, says trader Mark Messier.

08:32AM 01/22/13

Shorting Alexza Pharma On FDA's Adasuve Approval

By Mark Messier

Alexza is setting up as a classic biotech run-down stock, says trader Mark Messier.

07:00AM 12/19/12

Anacor Pharma: Run-Up Trade Into January Trial Data

By Mark Messier

Anacor will be releasing phase III results for a toenail fungus drug in January.

08:29AM 12/11/12

Hyperion Shares Poised to Run Up Ahead of FDA Decision

By Mark Messier

FDA expected to issue approval decision on orphan drug Ravicti on Jan. 23.

08:00AM 12/05/12

« Back
Page 1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 18,130.66 +89.12 0.49%
S&P 500 2,114.96 +10.76 0.51%
NASDAQ 5,066.43 +33.6790 0.67%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs